Literature DB >> 19381123

Nonalcoholic fatty liver disease and its association with cardiovascular disease.

Javier Lizardi-Cervera1, Daniel Aguilar-Zapata.   

Abstract

An association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) has been recently suggested. Indeed, different studies have demonstrated that NAFLD patients present increased subclinical atherosclerosis compared to non-steatosic individuals, and are supported by the few follow-up studies revealing that CVD is the second most common cause of death in NAFLD patients. However, the nature of the relationship NAFLD/CVD is still under debate.

Entities:  

Mesh:

Year:  2009        PMID: 19381123

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  20 in total

Review 1.  Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Melanie D Beaton
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

2.  Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease.

Authors:  Ivana Mikolasevic; Lidija Orlic; Sandra Milic; Vesna Lukenda; Sanjin Racki; Davor Stimac; Ervin Avdovic; Luka Zaputovic
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

Review 3.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

4.  Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.

Authors:  Ivana Mikolasevic; Sandra Milic; Sanjin Racki; Luka Zaputovic; Davor Stimac; Mladen Radic; Dean Markic; Lidija Orlic
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

5.  Ultrasound Diagnosis of Hepatic Steatosis as a Surrogate for Atherosclerosis.

Authors:  S Guth; E Windler; U Leise; C M Bamberger
Journal:  Ultrasound Int Open       Date:  2016-03-01

Review 6.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

7.  Combination drug treatment in patients with non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2010-04-27

Review 8.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

Review 9.  Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment.

Authors:  Howard P Monsour; Catherine T Frenette; Kathleen Wyne
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

Review 10.  Bariatric surgery for non-alcoholic steatohepatitis in obese patients.

Authors:  Norberto C Chavez-Tapia; Felix I Tellez-Avila; Tonatiuh Barrientos-Gutierrez; Nahum Mendez-Sanchez; Javier Lizardi-Cervera; Misael Uribe
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.